Get the Stockscreener App
3.06
6.25%
0.18
After Hours:
3.06
MAIA Biotechnology Inc stock is traded at $3.06, with a volume of 244.84K.
It is up +6.25% in the last 24 hours and up +20.95% over the past month.
MAIA Biotechnology, Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer. It is also developing second generation telomere targeting agents. MAIA Biotechnology, Inc. was incorporated in 2018 and is headquartered in Chicago, Illinois.
See More
Previous Close:
$2.88
Open:
$2.95
24h Volume:
244.84K
Relative Volume:
2.64
Market Cap:
$73.34M
Revenue:
-
Net Income/Loss:
$-19.77M
P/E Ratio:
-1.949
EPS:
-1.57
Net Cash Flow:
$-13.07M
1W Performance:
+12.50%
1M Performance:
+20.95%
6M Performance:
-6.71%
1Y Performance:
+43.66%
1-Day Range:
$2.9156
$3.20
1-Week Range:
$2.64
$3.20
52-Week Range:
$0.82
$5.99
MAIA Biotechnology Inc Stock (MAIA) Company Profile
Name
MAIA Biotechnology Inc
Sector
Industry
Phone
312 416 8592
Address
444 West Lake Street, Suite 1700, Chicago
MAIA Biotechnology Inc Stock (MAIA) Latest News
MAIA Biotechnology Announces Late-Breaking Abstract of THIO-101 Updates Selected for Oral and Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting - StockTitan
Maia Biotechnology director Stan Smith buys shares worth $250,999 - Investing.com
Maia Biotechnology director Stan Smith buys shares worth $250,999 By Investing.com - Investing.com Australia
Insider Buying: MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Director Acquires 22,133 Shares of Stock - MarketBeat
Director Cristian Luput Acquires 22,133 Shares of MAIA Biotechno - GuruFocus.com
Director Ramiro Guerrero Acquires 88,534 Shares of MAIA Biotechn - GuruFocus.com
Maia Biotechnology director Steven Chaouki buys $55,553 in shares - Investing.com
Maia Biotechnology director Luput acquires shares worth $55,553 By Investing.com - Investing.com Nigeria
Maia Biotechnology director Luput acquires shares worth $55,553 - Investing.com
Cosmo Metals Secures $500,000 for Strategic Expansion - MSN
Antipa Minerals Expands Share Offering on ASX - MSN
WAM Alternative Assets Expands ASX Securities Offering - MSN
Argent BioPharma Issues New Shares Amidst Strategic Growth - MSN
MAIA Biotechnology Announces $2.44 Million Private Placement - StockTitan
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.4%Here's What Happened - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.4% – Time to Sell? - Defense World
Alterity Therapeutics Prepares for 2024 Annual General Meeting - MSN
Li Bang International announces pricing of initial public offering - MSN
MAIA Biotechnology Announces Poster Presentation of Novel THIO Prodrugs at ENA 2024 Symposium on Molecular Targets and Cancer Therapeutics - BioSpace
MAIA Biotechnology (NYSEAMERICAN:MAIA) Trading Down 1.1% - MarketBeat
BioAge, BKV shares end their first trading day flat after earlier gains - MSN
Weight-loss drug developer BioAge Labs aims to raise $198M from U.S. IPO - MSN
Healthcare Stock Performance - Yahoo Finance
Short Interest in Biomea Fusion, Inc. (NASDAQ:BMEA) Expands By 7.8% - Defense World
Daiwa Securities Group Inc. Invests $82,000 in Haemonetics Co. (NYSE:HAE) - Defense World
Promising signs for MAIA’s telomere-targeting treatment - The Pharma Letter
Mayne Pharma Group (OTCMKTS:MAYNF) Shares Down 8% - Defense World
THIO Combo Yields Survival Benefit in Advanced NSCLC - AJMC.com Managed Markets Network
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of CAE - PR Newswire
Summit Therapeutics jumps 4%, raises $235M - MSN
MAIA Biotechnology Reports Promising Interim Results in Lung Cancer Treatment Study - Vancity Buzz
MAIA Biotechnology Inc’s latest rating changes from various analysts - Knox Daily
MAIA reports survival benefit in advanced lung cancer trial - Investing.com
MAIA Biotech releases Phase II results for THIO - The Pharma Letter
MAIA reports survival benefit in advanced lung cancer trial By Investing.com - Investing.com Australia
MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks
MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - StockTitan
MAIA Biotechnology, Inc. to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - Marketscreener.com
MAIA Biotechnology to Present New Phase 2 Clinical Trial Data at the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
MAIA Biotechnology (NYSEAMERICAN:MAIA) Stock Price Down 3.9% - MarketBeat
MAIA Biotechnology (NYSEAMERICAN:MAIA) Shares Down 3.9% - Defense World
MAIA Biotechnology Inc [MAIA] Investment Guide: What You Need to Know - Knox Daily
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Short Interest Down 13.9% in August - MarketBeat
Lazertinib With Amivantamab Approved by FDA for Use in NSCLC - AJMC.com Managed Markets Network
Mather Group LLC. Increases Stock Position in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) - Defense World
MAIA Biotechnology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 - Marketscreener.com
32,487 Shares in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Acquired by Virtu Financial LLC - Defense World
Mirum Pharma gains amid report of approach from Swedish Orphan Biovitrum - MSN
Officials Provide Update on Phase 2 Trial of THIO Plus Cemiplimab in NSCLC - DocWire News
Investing in MAIA Biotechnology Inc (MAIA): What You Must Know - Knox Daily
MAIA Biotechnology Inc Stock (MAIA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Cap:
|
Volume (24h):